M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Antonio Palumbo,Sara Bringhen,Alessandra Larocca,Davide Rossi,Francesco Di Raimondo,Valeria Magarotto,Francesca Patriarca,Anna Levi,Giulia Benevolo,Iolanda Vincelli,Mariella Grasso,Luca Franceschini,Daniela Gottardi,Renato Zambello,Vittorio Montefusco,Antonietta Falcone,Paola Omedè,Roberto Marasca,Fortunato Morabito,Roberto Mina,Tommasina Guglielmelli,Chiara Nozzoli,Roberto Passera,Gianluca Gaidano,Massimo Offidani,Roberto Ria,Maria Teresa Petrucci,Pellegrino Musto,Mario Boccadoro,Michele Cavo +29 more
TL;DR: Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation and were significantly more frequent in the VMPT-VT patients.
Journal ArticleDOI
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Monika Engelhardt,Evangelos Terpos,Martina Kleber,Ralph Wäsch,Gareth J. Morgan,Michele Cavo,Niels W.C.J. van de Donk,Andreas Beilhack,Benedetto Bruno,Hans Erik Johnsen,Roman Hájek,Christoph Driessen,Heinz Ludwig,Meral Beksac,Mario Boccadoro,Christian Straka,Sara Brighen,Martin Gramatzki,Alessandra Larocca,Henk M. Lokhorst,Valeria Magarotto,Fortunato Morabito,Meletios A. Dimopoulos,Hermann Einsele,Pieter Sonneveld,Antonio Palumbo +25 more
TL;DR: Recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence are presented.
Journal ArticleDOI
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
Paolo Corradini,Michele Cavo,Henk M. Lokhorst,Giovanni Martinelli,Carolina Terragna,Ignazio Majolino,P. Valagussa,Mario Boccadoro,Diana Samson,Andrea Bacigalupo,Nigel H. Russell,Vittorio Montefusco,Claudia Voena,Gösta Gahrton +13 more
TL;DR: It is believed that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival and to identify any clinical feature predictive of durable PCR-negativity.
Journal ArticleDOI
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen,Maria-Victoria Mateos,Sonja Zweegman,Alessandra Larocca,Antonietta Falcone,Albert Oriol,Davide Rossi,Maide Cavalli,Pierre W. Wijermans,Roberto Ria,Massimo Offidani,Juan José Lahuerta,Anna Marina Liberati,Roberto Mina,Vincenzo Callea,Martijn R. Schaafsma,Chiara Cerrato,Roberto Marasca,Luca Franceschini,Andrea Evangelista,Ana Isabel Teruel,Bronno van der Holt,Vittorio Montefusco,Giovannino Ciccone,Mario Boccadoro,Jesús F. San Miguel,Pieter Sonneveld,Antonio Palumbo +27 more
TL;DR: The risk of death was increased in patients aged 75 years or over or renal failure at presentation, occurrence of infections, cardiac or gastrointestinal adverse events negatively affected survival and more intensive approaches, such as the combination of bortezomib-thalidomide, negatively affected outcome.
Journal ArticleDOI
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
Jesús F. San-Miguel,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,H. Goldschmidt,Donna E. Reece,J. Bladé,Mario Boccadoro,Jamie Cavenagh,Rachel Neuwirth,Anthony Boral,Dixie Lee Esseltine,KC Anderson +18 more
TL;DR: Results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency, and is more effective than dexamethasone in overcoming the detrimental effect of renal impairment.